Clinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administrated in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
NCT05573802 is registered in ClinicalTrials.gov with Hellenic Society of Hematology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administrated in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
- Lead sponsor
- Hellenic Society of Hematology
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- July 14, 2023
- Completion date
- October 31, 2026
- Enrollment
- 36 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
blood protein disorders, corneal disease, gammopathy, monoclonal, haematologic disease, multiple myeloma, neoplasm, plasma cell, neoplasms, paraproteinemias